News and Trends 26 Jun 2017 Videos: Who won the Refresh Early-Stage Startup Battle? The Bonsai goes to… As you might have read in our recap, we had not one but two startup battles for the last edition of Refresh. Watch the companies’ pitches below! Up first was Cambridge Cancer Genomics, which uses AI to design personalised DNA-based tests to help clinicians to better track their patients’ responses to cancer drugs in order to make […] June 26, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2017 German Biotech Unveils Positive Phase II Results for Alzheimer’s Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead candidate PQ912 in patients with early Alzheimer’s Disease. The German biotech Probiodrug is pioneering new approaches to eliminate pyroglutamate (pGlu)-Abeta, a peptide that has been linked to the formation of toxic oligomers involved in Alzheimer’s disease. Now, the biotech came out […] June 12, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 10 Apr 2017 “Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer’s Disease without any success to show for its efforts. Now the sixth leading cause of death across all age groups, […] April 10, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […] April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2017 Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials? After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two new Phase III studies in Alzheimer’s with its antibody candidate gantenerumab, initially developed by the German biotech giant MorphoSys. The trials are expected to begin later this year, but Roche […] March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2017 Hopes are up: A Second Phase III Trial for Alzheimer’s Disease The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up with Genentech to bring its amyloid beta (Aβ)-targeting antibody crenezumab into the clinic. Although the compound did not meet its co-primary enpoints in the large phase II ABBY trial, Genentech pushed […] February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech bids for Crowdfunding in Neurodegenerative Disease AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […] February 15, 2017 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2017 A Dutch University Hospital has Halted Amyloid Beta Drug Studies Despite the popularity of amyloid beta-targeting drugs, none have managed to pass late stage clinical trials, prompting UMC Radboud to halt its own studies. In the latest blow to the amyloid beta hypothesis, Radboud University Medical Centre in Nijmegen, the Netherlands, announced that it will no longer continue studies into drugs targeting misfolded amyloid beta. These […] February 10, 2017 - 3 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2016 The 8 Biggest Biotech Medical Fails of 2016 in Europe Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […] December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 What Does ‘Anti-Aging Treatment’ Mean in Biotech? Beyond filling in wrinkles with cosmetics, how do you solve a problem like aging? Here’s how biotech is sinking its teeth into the challenge. “Aging is… broadly [defined] as the time-dependent functional decline that affects most living organisms.” Maria Blasco, Hallmarks of Aging. Can we treat aging directly with medicine? “For the past decade, pharma and […] December 20, 2016 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email